Cannabinoid-induced changes in respiration of brain mitochondria

Toxicology Letters

Volumn 231, Issue 1, 2014, Pages 62-71

  Fišar, Zdeněk ^a   Singh, Namrata ^a   Hroudová, Jana ^a  

^a CHARLES UNIVERSITY   (Czech Republic)

Author keywords

AM251; Anandamide; Cannabidiol; Respiratory rate; WIN 55,212 2; 9 Tetrahydrocannabinol

Indexed keywords

1 (2,4 DICHLOROPHENYL) 5 (4 IODOPHENYL) 4 METHYL N (1 PIPERIDYL) 1H PYRAZOLE 3 CARBOXAMIDE; 2 ARACHIDONOYLGLYCEROL; 2,3 DIHYDRO 5 METHYL 3 (MORPHOLINOMETHYL) 6 (1 NAPHTHOYL)PYRROLO[1,2,3 DE][1,4]BENZOXAZINE; ANANDAMIDE; CANNABIDIOL; CANNABINOID 1 RECEPTOR; CYTOCHROME C OXIDASE; DRONABINOL; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE DEHYDROGENASE (UBIQUINONE); SUCCINATE DEHYDROGENASE (UBIQUINONE); AMIDE; ARACHIDONIC ACID DERIVATIVE; BENZOXAZINE DERIVATIVE; CANNABINOID; CANNABINOID RECEPTOR AGONIST; ENDOCANNABINOID; MORPHOLINE DERIVATIVE; NAPHTHALENE DERIVATIVE; PIPERIDINE DERIVATIVE; PYRAZOLE DERIVATIVE;

ANIMAL TISSUE; ARTICLE; BRAIN MITOCHONDRION; CONCENTRATION (PARAMETERS); CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFICACY; DRUG MECHANISM; ENZYME ACTIVITY; ENZYME SUBSTRATE; EVIDENCE BASED PRACTICE; IC50; MITOCHONDRIAL RESPIRATION; NONHUMAN; PROTEIN FUNCTION; RECEPTOR AFFINITY; RESPIRATORY CHAIN; ANIMAL; BRAIN; CELL RESPIRATION; DOSE RESPONSE; DRUG EFFECTS; ENERGY METABOLISM; INVERSE AGONISM; METABOLISM; MITOCHONDRION; SIGNAL TRANSDUCTION; SWINE;

ANIMALS; ARACHIDONIC ACIDS; BENZOXAZINES; BRAIN; CANNABIDIOL; CANNABINOID RECEPTOR AGONISTS; CANNABINOIDS; CELL RESPIRATION; DOSE-RESPONSE RELATIONSHIP, DRUG; DRONABINOL; DRUG INVERSE AGONISM; ENDOCANNABINOIDS; ENERGY METABOLISM; MITOCHONDRIA; MORPHOLINES; NAPHTHALENES; PIPERIDINES; POLYUNSATURATED ALKAMIDES; PYRAZOLES; RECEPTOR, CANNABINOID, CB1; SIGNAL TRANSDUCTION; SWINE;

EID: 84908269088     PISSN: 03784274     EISSN: 18793169     Source Type: Journal    
DOI: 10.1016/j.toxlet.2014.09.002     Document Type: Article

References (82)

1. Acin-Perez R.G.L., Enriquez J.A. The function of the respiratory supercomplexes: the plasticity model. Biochim. Biophys. Acta 2014, 1837:444-450.
2. Alger B.E., Tang A.H. Do cannabinoids reduce brain power?. Nat. Neurosci. 2012, 15:499-501.
3. Aso E., Ferrer I. Cannabinoids for treatment of Alzheimer's disease: moving toward the clinic. Front. Pharmacol. 2014, 5:37. (eCollection).
4. Athanasiou A., Clarke A.B., Turner A.E., Kumaran N.M., Vakilpour S., Smith P.A., et al. Cannabinoid receptor agonists are mitochondrial inhibitors: a unified hypothesis of how cannabinoids modulate mitochondrial function and induce cell death. Biochem. Biophys. Res. Commun. 2007, 364:131-137.
5. Barnett-Norris J., Guarnieri F., Hurst D.P., Reggio P.H. Exploration of biologically relevant conformations of anandamide, 2-arachidonylglycerol, and their analogues using conformational memories. J. Med. Chem. 1998, 41:4861-4872.
6. 9-tetrahydrocannabinol on mitochondrial NADH-oxidase activity. J. Biol. Chem. 1976, 251:5002-5006.
7. 1 receptors regulate neuronal energy metabolism. Nat. Neurosci. 2012, 15:558-564.
8. Bender E., Kadenbach B. The allosteric ATP-inhibition of cytochrome c oxidase activity is reversibly switched on by cAMP-dependent phosphorylation. FEBS Lett. 2000, 466:130-134.
9. Brand M.D., Nicholls D.G. Assessing mitochondrial dysfunction in cells. Biochem. J. 2011, 435:297-312.
10. Brunner G., Bygrave F.L. Microsomal marker enzymes and their limitations in distinguishing the outer membrane of rat liver mitochondria from the microsomes. Eur. J. Biochem. 1969, 8:530-534.
11. Catanzaro G., Rapino C., Oddi S., Maccarrone M. Anandamide increases swelling and reduces calcium sensitivity of mitochondria. Biochem. Biophys. Res. Commun. 2009, 388:439-442.
12. Chaban Y., Boekema E.J., Dudkina N.V. Structures of mitochondrial oxidative phosphorylation supercomplexes and mechanisms for their stabilisation. Biochim. Biophys. Acta 2014, 1837:418-426.
13. Clark J.B., Nicklas W.J. The metabolism of rat brain mitochondria: preparation and characterization. J. Biol. Chem. 1970, 245:4724-4731.
14. Devane W.A., Dysarz F.A., Johnson M.R., Melvin L.S., Howlett A.C. Determination and characterization of a cannabinoid receptor in rat brain. Mol. Pharmacol. 1988, 34:605-613.
15. Fagan S.G., Campbell V.A. The influence of cannabinoids on generic traits of neurodegeneration. Br. J. Pharmacol. 2014, 171:1347-1360.
16. Ferguson C.S., Tyndale R.F. Cytochrome P450 enzymes in the brain: emerging evidence of biological significance. Trends Pharmacol. Sci. 2011, 32:708-714.
17. Fišar Z. Inhibition of monoamine oxidase activity by cannabinoids. Naunyn Schmiedebergs Arch. Pharmacol. 2010, 381:563-572.
18. Fišar Z. Cannabinoids and monoamine neurotransmission with focus on monoamine oxidase. Prog. Neuropsychopharmacol. Biol. Psychiatry 2012, 38:68-77.
19. Fowler C.J., Rojo M.L., Rodriguez-Gaztelumendi A. Modulation of the endocannabinoid system: neuroprotection or neurotoxicity?. Exp. Neurol. 2010, 224:37-47.
20. Gatley S.J., Lan R., Pyatt B., Gifford A.N., Volkow N.D., Makriyannis A. Binding of the non-classical cannabinoid CP 55,940, and the diarylpyrazole AM251 to rodent brain cannabinoid receptors. Life Sci. 1997, 61:191-197.
21. Genova M.L., Lenaz G. Functional role of mitochondrial respiratory supercomplexes. Biochim. Biophys. Acta 2014, 1837:427-443.
22. 1 receptor. Mol. Metab. 2014, 3:495-504.
23. Hebert-Chatelain E., Reguero L., Puente N., Lutz B., Chaouloff F., Rossignol R., et al. Studying mitochondrial CB1 receptors: yes we can. Mol. Metab. 2014, 3:339.
24. Howlett A.C., Reggio P.H., Childers S.R., Hampson R.E., Ulloa N.M., Deutsch D.G. Endocannabinoid tone versus constitutive activity of cannabinoid receptors. Br. J. Pharmacol. 2011, 163:1329-1343.
25. Hroudová J., Fišar Z. In vitro inhibition of mitochondrial respiratory rate by antidepressants. Toxicol. Lett. 2012, 213:345-352.
26. Huestis M.A. Human cannabinoid pharmacokinetics. Chem. Biodivers. 2007, 4:1770-1804.
27. Kanabus M., Heales S.J., Rahman S. Development of pharmacological strategies for mitochondrial disorders. Br. J. Pharmacol. 2014, 171:1798-1817.
28. Kano M., Ohno-Shosaku T., Hashimotodani Y., Uchigashima M., Watanabe M. Endocannabinoid-mediated control of synaptic transmission. Physiol. Rev. 2009, 89:309-380.
29. Katona I., Sperlágh B., Sík A., Käfalvi A., Vizi E.S., Mackie K., et al. Presynaptically located CB1 cannabinoid receptors regulate GABA release from axon terminals of specific hippocampal interneurons. J. Neurosci. 1999, 19:4544-4558.
30. Lapuente-Brun E., Moreno-Loshuertos R., Acín-Pérez R., Latorre-Pellicer A., Colás C., Balsa E., et al. Supercomplex assembly determines electron flux in the mitochondrial electron transport chain. Science 2013, 340:1567-1570.
31. Lenaz G. Lipid fluidity and membrane protein dynamics. Biosci. Rep. 1987, 7:823-837.
32. Leuschner J.T., Wing D.R., Harvey D.J., Brent G.A., Dempsey C.E., Watts A., et al. The partitioning of delta 1-tetrahydrocannabinol into erythrocyte membranes in vivo and its effect on membrane fluidity. Experientia 1984, 40:866-868.
33. Lipina C., Irving A.J., Hundal H.S. Mitochondria: a possible nexus for the regulation of energy homeostasis by the endocannabinoid system?. Am. J. Physiol. Endocrinol. Metab. 2014, 307:E1-E13.
34. Lowry O.H., Rosebrough N.J., Farr A.L., Randall R.J. Protein measurement with the Folin phenol reagent. J. Biol. Chem. 1951, 193:265-275.
35. Maccarrone M., Bernardi G., Agrò A.F., Centonze D. Cannabinoid receptor signalling in neurodegenerative diseases: a potential role for membrane fluidity disturbance. Br. J. Pharmacol. 2011, 163:1379-1390.
36. Maione S., Costa B., Di Marzo V. Endocannabinoids: a unique opportunity to develop multitarget analgesics. Pain 2013, 154(Suppl. 1):S87-S93.
37. Marsicano G., Lutz B. Neuromodulatory functions of the endocannabinoid system. J. Endocrinol. Invest. 2006, 29:27-46.
38. Martin B.R. Cellular effects of cannabinoids. Pharmacol. Rev. 1986, 38:45-74.
39. Mattson M.P., Gleichmann M., Cheng A. Mitochondria in neuroplasticity and neurological disorders. Neuron 2008, 60:748-766.
40. Mavromoustakos T., Papahatjis D., Laggner P. Differential membrane fluidization by active and inactive cannabinoid analogues. Biochim. Biophys. Acta 2001, 1512:183-190.
41. Mechoulam R., Peters M., Murillo-Rodriguez E., Hanuš L.O. Cannabidiol - recent advances. Chem. Biodivers. 2007, 4:1678-1692.
42. Miller E.K., Dawson R.M. Can mitochondria and synaptosomes of guinea-pig brain synthesize phospholipids?. Biochem. J. 1972, 126:805-821.
43. Morena M., Campolongo P. The endocannabinoid system: an emotional buffer in the modulation of memory function. Neurobiol. Learn. Mem. 2014, 112:30-43.
44. Morgan N., Stanford H., Woodhall I.M. Functional CB2 type cannabinoid receptors at CNS synapses. Neuropharmacology 2009, 57:356-368.
45. Morozov Y.M., Dominguez M.H., Varela L., Shanabrough M., Koch M., Horvath T.L., et al. Antibodies to cannabinoid type 1 receptor co-react with stomatin-like protein 2 in mouse brain mitochondria. Eur. J. Neurosci. 2013, 38:2341-2348.
46. 1 receptors. Mol. Metab. 2014, 3:338.
47. Onaivi E.S., Ishiguro H., Gong J.P., Patel S., Perchuk A., Meozzi P.A., et al. Discovery of the presence and functional expression of cannabinoid CB2 receptors in brain. Ann. N. Y. Acad. Sci. 2006, 1074:514-536.
48. Pacher P., Bátkai S., Kunos G. The endocannabinoid system as an emerging target of pharmacotherapy. Pharmacol. Rev. 2006, 58:389-462.
49. Pacher P., Kunos G. Modulating the endocannabinoid system in human health and disease-successes and failures. FEBS J. 2013, 280:1918-1943.
50. Papa S., Rasmo D.D., Technikova-Dobrova Z., Panelli D., Signorile A., Scacco S., et al. Respiratory chain complex I, a main regulatory target of the cAMP/PKA pathway is defective in different human diseases. FEBS Lett. 2012, 586:568-577.
51. Paradies G., Paradies V., De Benedictis V., Ruggiero F.M., Petrosillo G. Functional role of cardiolipin in mitochondrial bioenergetics. Biochim. Biophys. Acta 2014, 1837:408-417.
52. Pertwee R.G. Emerging strategies for exploiting cannabinoid receptor agonists as medicines. Br. J. Pharmacol. 2009, 156:397-411.
53. 1 and CB[U+2082]. Pharmacol. Rev. 2010, 62:588-631.
54. Pesta D., Gnaiger E. High-resolution respirometry: OXPHOS protocols for human cells and permeabilized fibers from small biopsies of human muscle. Methods Mol. Biol. 2012, 810:25-58.
55. Pfeiffer K., Gohil V., Stuart R.A., Hunte C., Brandt U., Greenberg M.L., et al. Cardiolipin stabilizes respiratory chain supercomplexes. J. Biol. Chem. 2003, 278:52873-52880.
56. Pinna G., Broedel O., Eravci M., Stoltenburg-Didinger G., Plueckhan H., Fuxius S., et al. Thyroid hormones in the rat amygdala as common targets for antidepressant drugs, mood stabilizers, and sleep deprivation. Biol. Psychiatry 2003, 54:1049-1059.
57. Piomelli D. The molecular logic of endocannabinoid signalling. Nat. Rev. Neurosci. 2003, 4:873-884.
58. Piscitelli F., Di Marzo V. Redundancy of endocannabinoid inactivation: new challenges and opportunities for pain control. ACS Chem. Neurosci. 2012, 3:356-363.
59. Rosca M.G., Hoppel C.L. Mitochondria in heart failure. Cardiovasc. Res. 2010, 88:40-50.
60. Sardanelli A.M., Signorile A., Nuzzi R., Rasmo D.D., Technikova-Dobrova Z., Drahota Z., et al. Occurrence of A-kinase anchor protein and associated cAMP-dependent protein kinase in the inner compartment of mammalian mitochondria. FEBS Lett. 2006, 580:5690-5696.
61. Sarne Y., Asaf F., Fishbein M., Gafni M., Keren O. The dual neuroprotective-neurotoxic profile of cannabinoid drugs. Br. J. Pharmacol. 2011, 163:1391-1401.
62. Schägger H., Pfeiffer K. Supercomplexes in the respiratory chains of yeast and mammalian mitochondria. EMBO J. 2000, 19:1777-1783.
63. Schmid P.C., Krebsbach R.J., Perry S.R., Dettmer T.M., Maasson J.L., Schmid H.H. Occurrence and postmortem generation of anandamide and other long-chain N-acylethanolamines in mammalian brain. FEBS Lett. 1995, 375:117-120.
64. Silvestri C., Di Marzo V. The endocannabinoid system in energy homeostasis and the etiopathology of metabolic disorders. Cell Metab. 2013, 17:475-490.
65. Srere P.A. [1] Citrate synthase: [EC 4.1.3.7. Citrate oxaloacetate-lyase., (CoA-acetylating)]. Methods Enzymol. 1969, 13:3-11.
66. Stella N. Cannabinoid and cannabinoid-like receptors in microglia, astrocytes, and astrocytomas. Glia 2010, 1017-1030. 10.1002/glia.20983.
67. Szabo B., Dörner L., Pfreundtner C., Nörenberg W., Starke K. Inhibition of GABAergic inhibitory postsynaptic currents by cannabinoids in rat corpus striatum. Neuroscience 1998, 85:395-403.
68. Szeto H.H. First-in-class cardiolipin-protective compound as a therapeutic agent to restore mitochondrial bioenergetics. Br. J. Pharmacol. 2014, 171:2029-2050.
69. Technikova-Dobrova Z., Sardanelli A.M., Speranza F., Scacco S., Signorile A., Lorusso V., et al. Cyclic adenosine monophosphate-dependent phosphorylation of mammalian mitochondrial proteins: enzyme and substrate characterization and functional role. Biochemistry 2001, 40:13941-13947.
70. 2H NMR. Biochim. Biophys. Acta 2011, 1808:2095-2101.
71. Trezza V., Campolongo P. The endocannabinoid system as a possible target to treat both the cognitive and emotional features of post-traumatic stress disorder (PTSD). Front. Behav. Neurosci. 2013, 7:100.
72. 1 cannabinoid receptor. J. Mol. Endocrinol. 2010, 44:75-85.
73. Vallée M., Vitiello S., Bellocchio L., Hébert-Chatelain E., Monlezun S., Martin-Garcia E., et al. Pregnenolone can protect the brain from cannabis intoxication. Science 2014, 343:94-98.
74. Velenovská M., Fišar Z. Effect of cannabinoids on platelet serotonin uptake. Addict. Biol. 2007, 12:158-166.
75. Waczulikova I., Habodaszova D., Cagalinec M., Ferko M., Ulicna O., Mateasik A., et al. Mitochondrial membrane fluidity, potential, and calcium transients in the myocardium from acute diabetic rats. Can. J. Physiol. Pharmacol. 2007, 85:372-381.
76. Wasilewski M., Wieckowski M.R., Dymkowska D., Wojtczak L. Effects of N-acylethanolamines on mitochondrial energetics and permeability transition. Biochim. Biophys. Acta 2004, 1657:151-163.
77. Whittaker V.P. The synaptosome. Handbook of Neurochemistry Vol. II Structural Neurochemistry 1969, 327-364. Plenum Press, New York, London. A. Lajtha (Ed.).
78. Whyte D.A., Al-Hammadi S., Balhaj G., Brown O.M., Penefsky H.S., Souid A.K. Cannabinoids inhibit cellular respiration of human oral cancer cells. Pharmacology 2010, 85:328-335.
79. Wieckowski M.R., Giorgi C., Lebiedzinska M., Duszynski J., Pinton P. Isolation of mitochondria-associated membranes and mitochondria from animal tissues and cells. Nat. Protoc. 2009, 4:1582-1590.
80. Yadava N., Potluri P., Scheffler I.E. Investigations of the potential effects of phosphorylation of the MWFE and ESSS subunits on complex I activity and assembly. Int. J. Biochem. Cell Biol. 2008, 40:447-460.
81. Zaccagnino P., D'Oria S., Romano L.L., Di Venere A., Sardanelli A.M., Lorusso M. The endocannabinoid 2-arachidonoylglicerol decreases calcium induced cytochrome c release from liver mitochondria. J. Bioenerg. Biomembr. 2012, 44:273-280.
82. Zhang Y., Tian F., Xiao Q., Hu Y., Li J., Jiang F., et al. Exploiting the role of resveratrol in rat mitochondrial permeability transition. J. Membr. Biol. 2013, 246:365-373.